IRIS

To evaluate the efficacy of intravitreal ranibizumab in the treatment of myopic choroidal neovascularization (mCNV) complicated by vitreoretinal interface alterations.

HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION / Iacono, Pierluigi; Battaglia Parodi, Maurizio; Iuliano, Lorenzo; Bandello, Francesco. - In: RETINA. - ISSN 0275-004X. - 38:1(2018), pp. 84-90-90. [10.1097/IAE.0000000000001500]

HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION

Battaglia Parodi, Maurizio;Bandello, Francesco
2018-01-01

Abstract

To evaluate the efficacy of intravitreal ranibizumab in the treatment of myopic choroidal neovascularization (mCNV) complicated by vitreoretinal interface alterations.
2018
Adult; Aged; Angiogenesis Inhibitors; Bevacizumab; Choroidal Neovascularization; Female; Fluorescein Angiography; Humans; Intravitreal Injections; Macula Lutea; Male; Middle Aged; Myopia, Degenerative; Prospective Studies; Ranibizumab; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Vitreous Body; Visual Acuity
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/80552
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 6
social impact